Scarica l'app Stockscreener
5.84
0.69%
0.04
Dopo l'orario di chiusura:
5.70
-0.14
-2.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$5.80
Aprire:
$5.89
Volume 24 ore:
156.47K
Relative Volume:
0.85
Capitalizzazione di mercato:
$31.07M
Reddito:
$7.97M
Utile/perdita netta:
$-75.74M
Rapporto P/E:
-0.2405
EPS:
-24.2853
Flusso di cassa netto:
$-85.33M
1 W Prestazione:
+30.36%
1M Prestazione:
+27.79%
6M Prestazione:
-69.54%
1 anno Prestazione:
-64.34%
Intervallo 1D:
$5.57
$6.08
Intervallo di 1 settimana:
$4.60
$6.45
Portata 52W:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Confronta ALGS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.84 | 27.39M | 7.97M | -75.74M | -85.33M | -24.29 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-19 | Iniziato | H.C. Wainwright | Buy |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-09 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Ripresa | Piper Sandler | Overweight |
| 2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Iniziato | JP Morgan | Overweight |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Aligos Therapeutics Issues 26,000-Share Inducement Grant To New Employee - Nasdaq
Aligos Therapeutics (ALGS) Awards New Employee Stock Option Gran - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ALGS Stock News - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Expands Liver Disease Team with Strategic Hire, Awards 26,000 Share Options - Stock Titan
Aligos Therapeutics First Quarter 2025 Earnings: Revenues Miss Expectations - Yahoo Finance
Aligos reports promising HBV treatment data at EASL Congress - Investing.com
Aligos Therapeutics (ALGS) Showcases Promising HBV Treatment Results at EASL Congress 2025 | ALGS Stock News - GuruFocus
Aligos reports promising HBV treatment data at EASL Congress By Investing.com - Investing.com Nigeria
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 - The Manila Times
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results - ADVFN
Aligos Therapeutics Reports Strong Q1 2025 Progress - TipRanks
Aligos Therapeutics (ALGS) Reports Lower Q1 Revenue, Advances Ke - GuruFocus
Aligos Therapeutics Inc Reports Q1 2025 EPS of $5.12, Surpassing Estimates; Revenue Slightly Misses at $0.31 Million - GuruFocus
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
ALIGOS THERAPEUTICS Earnings Results: $ALGS Reports Quarterly Earnings - Nasdaq
Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView
Aligos Reports Surprise $43M Profit: Breakthrough HBV Drug Shows 100% Response Rate at 96 Weeks - Stock Titan
Aligos Therapeutics secures $105 million in private placement - MSN
Aligos Therapeutics (ALGS) Projected to Post Earnings on Tuesday - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stake Lessened by Renaissance Technologies LLC - Defense World
Aligos Therapeutics Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Gains Buy Rating with Promising Outlo - GuruFocus
Aligos Therapeutics (ALGS) Coverage Initiated with Positive Outl - GuruFocus
Wells Fargo & Company MN Invests $869,000 in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Geode Capital Management LLC Buys 3,197 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Aligos Therapeutics Q1 2025 Earnings: Clinical Stage Biotech Reports Pre-Market May 6Key Focus Areas - Stock Titan
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 - The Manila Times
When the Price of (ALGS) Talks, People Listen - news.stocktradersdaily.com
ALGS stock touches 52-week low at $4.21 amid market challenges By Investing.com - Investing.com South Africa
ALGS stock touches 52-week low at $4.21 amid market challenges - Investing.com India
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% - MSN
(ALGS) Investment Analysis - news.stocktradersdaily.com
ALGS stock touches 52-week low at $6.71 amid market challenges By Investing.com - Investing.com South Africa
ALGS stock touches 52-week low at $6.71 amid market challenges - Investing.com
Charles Schwab Investment Management Inc. Buys 2,306 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Receives “Buy” Rating from HC Wainwright - Defense World
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Aligos Therapeutics Inc Files For Offering Of Up To 6.2 Million Common Shares By The Selling SecurityholdersSEC Filing - TradingView
(ALGS) Long Term Investment Analysis - news.stocktradersdaily.com
Aligos Therapeutics Presents Positive Data at APASL 2025 - The Manila Times
Clinical Trial Success: Aligos' Dual Breakthroughs in Liver Disease Show 100% Efficacy - Stock Titan
Ten option delistings on March 24th - TipRanks
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
ALG-097558 confirmed as an effective pan-coronavirus strategy - BioWorld MedTech
Learn to Evaluate (ALGS) using the Charts - news.stocktradersdaily.com
Aligos Therapeutics Expands Team with Strategic Stock Option Package - Stock Titan
HC Wainwright Issues Negative Outlook for ALGS Earnings - Defense World
Financial Comparison: Achilles Therapeutics (NASDAQ:ACHL) vs. Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):